← Back to Search

Personalized Exercise Programs for Aging-related Functional Decline During Hospitalization

N/A
Recruiting
Led By Marie-Jeanne Kergoat, M.D., FRCPC
Research Sponsored by Université du Québec a Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
be aged 65 and over
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will help to determine if physical activity programs should be implemented in geriatric units to help the elderly maintain their functional capacities and mobility.

Who is the study for?
This trial is for older adults aged 65 and over who are hospitalized, planning to be discharged home, can communicate in French or English, have self-awareness, and no contraindications to physical activity. There are no specific exclusion criteria.
What is being tested?
The study tests three personalized exercise programs: MATCH during hospitalization; PATH at discharge; and PATH 2.0 both during hospitalization and after discharge. The goal is to prevent functional decline in elderly patients by integrating these exercises into routine care.
What are the potential side effects?
Since the interventions involve personalized exercise programs designed for the elderly, side effects may include typical risks associated with physical activity such as muscle soreness or fatigue but will be tailored to minimize any potential harm.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 65 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in muscle strength after intervention (upper muscle strength : handgrip strength, lower limb strength: sit to stand-30sec)
Changes in short physical performance battery (SPPB) after intervention
Changes in walking after intervention (Walking speed :4 m habitual gait speed and walking parameter : 3 meter timed up and go)
Secondary study objectives
Acceptability of the clinical tools: MATCH, PATH, PATH 2.0
Changes in caregiver burden after intervention
Changes in the length of stay after intervention
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Group 3Experimental Treatment1 Intervention
MATCH tool: Prescription of physical exercise programs during hospitalization
Group II: Group 2Experimental Treatment1 Intervention
PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
Group III: Group 1Experimental Treatment1 Intervention
PATH Tool : Prescription of exercise programs at discharge
Group IV: Group 4Active Control1 Intervention
Control group: Usual care by the clinical teams

Find a Location

Who is running the clinical trial?

Université du Québec a MontréalLead Sponsor
24 Previous Clinical Trials
4,685 Total Patients Enrolled
2 Trials studying Aging
126 Patients Enrolled for Aging
Marie-Jeanne Kergoat, M.D., FRCPCPrincipal InvestigatorCentre de recherche de l'institut Universitaire de Gériatrie de Montreal
Fonseca Raquel, Ph. DPrincipal InvestigatorUniversité du Québec a Montréal
Veillette Nathalie, Ph.DPrincipal InvestigatorUniversité de Montréal
Mylene Aubertin-Leheudre, Ph. DPrincipal InvestigatorUniversité du Québec a Montréal

Media Library

MATCH Clinical Trial Eligibility Overview. Trial Name: NCT04078334 — N/A
Aging Clinical Trial 2023: MATCH Highlights & Side Effects. Trial Name: NCT04078334 — N/A
MATCH 2023 Treatment Timeline for Medical Study. Trial Name: NCT04078334 — N/A
Aging Research Study Groups: Group 4, Group 2, Group 1, Group 3
~139 spots leftby Dec 2025